Physician profile
Gary S Wallace
NPI 1427083633
$8,699.50
in general payments reported to CMS, 2019-2025
46 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,401 · 2020: $2,116 · 2021: $2,571 · 2022: $1,574 · 2023: $37.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $37.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $37.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,118.05 | 2019-2022 | |
| Novo Nordisk INC | $1,060.37 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $841.24 | 2019-2022 | |
| Glaxosmithkline, LLC. | $840.40 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $787.40 | 2019-2022 | |
| Pfizer INC. | $442.10 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $326.97 | 2019-2022 | |
| Amarin Pharma, INC. | $325.37 | 2019-2021 | |
| Amgen INC. | $275.72 | 2019-2022 | |
| Lilly USA, LLC | $264.69 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $259.60 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $226.49 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $183.98 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $163.12 | 2019-2021 | |
| Abbott Laboratories | $157.03 | 2020-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.